Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus
Open Access
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 147, 157-165
- https://doi.org/10.1016/j.diabres.2018.10.024
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 14 references indexed in Scilit:
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-upDiabetes Care, 2016
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineExpert Opinion on Drug Metabolism & Toxicology, 2015
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia, 2015
- The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 DiabetesThe Diabetes Educator, 2014
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine SocietyDiabetes Care, 2013
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trialsDiabetes, Obesity and Metabolism, 2012
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2011
- Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country surveyJournal of Medical Economics, 2011
- Patient perspectives on once-weekly medications for diabetesDiabetes, Obesity and Metabolism, 2010
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008